Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
ln Vitro |
In order to produce M1-like (iNOS+) and M2-like (arginase+) macrophages, Raw264.7 macrophages were activated for 24 hours with either 10 ng/mL LPS or 10 ng/mL IL-10 [1]. The cell viability of M1 macrophages is inhibited by momordicoside G (10–40 μM; 24 h), while M2 macrophages are not affected. In vitro, momordicoside G (40 μM) causes M1 macrophages to undergo apoptosis, lowers NO levels, and raises IL-12, IL-10, and TGF-β levels [1]. Momordicoside G (40 μM) inhibits the amount of the autophagy-related marker LC3-B at the protein level [1].
|
---|---|
ln Vivo |
In the lung carcinogenesis model of ICR mice, urethane (HY-B1207) (600 mg/kg; intraperitoneal injection; once weekly for 4 or 8 weeks) or LPS (HY-D1056) (2 mg/kg; intratracheal administration) and 4 mg/mouse IEC (intraperitoneal injection) induction were used [1]. In a mouse lung carcinogenesis model, momordicoside G (50 mg/kg; oral; once daily for 4 or 8 weeks) inhibits the development of malignant lesions and urethane-induced lung damage [1]. In a model of lung damage generated by lipoprotein stress (LPS), momordicoside G (50 mg/kg; oral; once daily for 2 weeks) facilitates the repair of lung damage [1].
|
Cell Assay |
Cell Viability Assay[1]
Cell Types: M1 macrophages, M2 macrophages Tested Concentrations: 10 μM, 20 μM, 40 μM Incubation Duration: 24 hrs (hours) Experimental Results: Selectively diminished the cell viability of M1 macrophages, instead of M2 macrophages. |
Animal Protocol |
Animal/Disease Models: Mouse lung carcinogenic model: Urethane-induced lung carcinogenic model and LPS-induced lung injury model[1]
Doses: 50 mg/kg Route of Administration: po (oral gavage); one time/day for 4 or 8 weeks Experimental Results: Affected inflammasome and cytokines during urethane-induced lung injury and carcinoma lesions. Exhibits macrophage-regulating capacity in LPS-induced lung injury model. |
References |
[1]. Du Z, et al. Momordicoside G Regulates Macrophage Phenotypes to Stimulate Efficient Repair of Lung Injury and Prevent Urethane-Induced Lung Carcinoma Lesions. Front Pharmacol. 2019 Mar 29;10:321.
|
Molecular Formula |
C37H60O8
|
---|---|
Molecular Weight |
632.87
|
CAS # |
81371-54-2
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CC(C1C2(C)C(C3C4(C5CCC(C(C)(C)C5(OC4)C=C3)OC3C(O)C(O)C(O)C(CO)O3)CC2)(C)CC1)C/C=C\C(OC)(C)C
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.5801 mL | 7.9005 mL | 15.8010 mL | |
5 mM | 0.3160 mL | 1.5801 mL | 3.1602 mL | |
10 mM | 0.1580 mL | 0.7901 mL | 1.5801 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.